Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 538

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases

Open access
Beeton, Christine, Wulff, Heike, Standifer, Nathan E., Azam, Philippe, Mullen, Katherine M., Pennington, Michael W., Kolski-Andreaco, Aaron, Wei, Eric, Grino, Alexandra, Counts, Debra R., Wang, Ping H., LeeHealey, Christine J., S. Andrews, Brian, Sankaranarayanan, Ananthakrishnan, Homerick, Daniel, Roeck, Werner W., Tehranzadeh, Jamshid, Stanhope, Kimber L., Zimin, Pavel, Havel, Peter J., Griffey, Stephen, Knaus, Hans-Guenther, Nepom, Gerald T., Gutman, George A., Calabresi, Peter A., Chandy, K. George·2006·Proceedings of the National Academy of Sciences

Abstract

Autoreactive memory T lymphocytes are implicated in the pathogenesis of autoimmune diseases. Here we demonstrate that disease-associated autoreactive T cells from patients with type-1 diabetes mellitus or rheumatoid arthritis (RA) are mainly CD4+CCR7−CD45RA−effector memory T cells (T EM cells) with elevated Kv1.3 potassium channel expression. In contrast, T cells with other antigen specificities from these patients, or autoreactive T cells from healthy individuals and disease controls, express low levels of Kv1.3 and are predominantly naïve or central-memory (T CM) cells. In T EM cells, Kv1.3 traffics to the immunological synapse during antigen presentation where it colocalizes with Kvβ2, SAP97, ZIP, p56 lck, and CD4. Although Kv1.3 inhibitors [ShK(L5)-amide (SL5) and PAP1] do not prevent immunological synapse formation, they suppress Ca 2+-signaling, cytokine production, and proliferation of autoantigen-specific T EM cells at pharmacologically relevant concentrations while sparing other classes of T cells. Kv1.3 inhibitors ameliorate pristane-induced arthritis in rats and reduce the incidence of experimental autoimmune diabetes in diabetes-prone (DP-BB/W) rats. Repeated dosing with Kv1.3 inhibitors in rats has not revealed systemic toxicity. Further development of Kv1.3 blockers for autoimmune disease therapy is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0605136103

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Cited by

See all 538

Metadata

Authors
Beeton, C., Wulff, H., Standifer, N. E., Azam, P., Mullen, K. M., Pennington, M. W., Kolski-Andreaco, A., Wei, E., Grino, A., Counts, D. R., Wang, P. H., LeeHealey, C. J., S. Andrews, B., Sankaranarayanan, A., Homerick, D., Roeck, W. W., Tehranzadeh, J., Stanhope, K. L., Zimin, P., Havel, P. J., Griffey, S., Knaus, H.-G., Nepom, G. T., Gutman, G. A., Calabresi, P. A., & Chandy, K. G.
Venue
Proceedings of the National Academy of Sciences
Published
2006-11-14
Volume
103
Issue
46
Pages
17414-17419
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2019310318
Cited by
538
References
65
FWCI
7.61
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. https://app.cochat.ai/papers/10.1073/pnas.0605136103
The paper
Beeton, C., Wulff, H., Standifer, N. E., Azam, P., Mullen, K. M., Pennington, M. W., Kolski-Andreaco, A., Wei, E., Grino, A., Counts, D. R., Wang, P. H., LeeHealey, C. J., S. Andrews, B., Sankaranarayanan, A., Homerick, D., Roeck, W. W., Tehranzadeh, J., Stanhope, K. L., Zimin, P., . . . Chandy, K. G. (2006). Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0605136103

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.